Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2019063844) VACCINATION CONTRE LE VIRUS RESPIRATOIRE SYNCYTIAL
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

CLAIMS

1 . A vaccine comp sing:

- a human Respiratory Syncytial Virus (RSV) F nucleic acid sequence or (glyco)protein or peptide encoded therefrom; or

- a virus comp sing a human Respiratory Syncytial Virus (RSV) F nucleic acid sequence or

(glyco)protein or peptide encoded therefrom;

wherein said nucleic acid sequence has a modification in the p27 encoded region, and wherein said modification is a removal of an N-glycosylation site in said p27 encoded region.

2. The vaccine as defined in claim 1 ; wherein said modification consists of the amino acid substitution of asparagine into glutamine, alanine, or any other amino acid except for asparagine, at said N-glycosylation site in the p27 encoded region.

3. The vaccine as defined in anyone of claims 1 to 2; wherein said modification is selected from the list comphsing: removal of the N1 16 glycosylation site in the p27 encoded region, removal of the N120 glycosylation site in the p27 encoded region, removal of the N126 glycosylation site in the p27 encoded region, or a combination thereof.

4. The vaccine as defined in anyone of claims 1 to 3; wherein said modification is selected from the list comphsing: N1 16Q in the p27 encoded region, N120Q in the p27 encoded region, N126Q in the p27 encoded region, or a combination thereof.

5. The vaccine as defined in any one of claims 1 to 4, further comprising one or more additional modifications in the F1 encoded region and/or the F2 encoded region.

6. The vaccine as defined in claim 5, wherein said one or more further modifications result in removal of a further N-glycosylation site in said F1 encoded region and/or F2 encoded region.

7. The vaccine as defined in claim 6, wherein said further modification is selected from the list comphsing: removal of the N27 glycosylation site of the F2 encoded region, removal of the N70 glycosylation site of the F2 encoded region, removal of the N500 glycosylation site of the F1 encoded region, or a combination thereof.

8. The vaccine as defined in claim 7, wherein said further modification is selected from the list comphsing N27Q in the encoded region, N70Q in the encoded region, N500Q in the encoded region or a combination thereof.

9. A virus comprising a human RSV nucleic acid sequence or (glyco)protein or peptide encoded therefrom; wherein said nucleic acid sequence has a modification in the p27 encoded region, and wherein said modification results in removal of an N-glycosylation site in said p27 encoded region.

10. The vaccine as defined in anyone of claims 1 -8 or the virus as defined in claim 9 for use in human or veterinary medicine.

1 1 . The vaccine as defined in anyone of claims 1 -8 or the virus as defined in claim 9 for use in the prophylaxis and/or treatment of an RSV infection in a subject in need thereof.

12. A method for the prophylaxis and/or treatment of human RSV infections comprising administering to a subject in need thereof, a vaccine as defined in anyone of claims 1 -8, or a virus as defined in claim 9.